Two-time-point FDG PET/CT: liver SULmean repeatability.

OBJECTIVE. The purpose of this study was to evaluate the repeatability of liver mean standardized uptake value normalized to lean body mass (SULmean) in the same patients at different time points within the right lobe of the liver at (18)F-FDG PET/CT, in a clinical setting. MATERIALS AND METHODS.

18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management.

Unlabelled: The Centers for Medicare and Medicaid Services recently ruled that only 3 posttherapy follow-up (18)F-FDG PET/CT scans are funded for a tumor type per patient and any additional follow-up PET/CT scans will be funded at the discretion of the local Medicare administrator. The purpose of this study was to evaluate the added value of 4 or more follow-up PET/CT scans to clinical assessment and impact on patient management.

Methods: This was an institutional review board-approved, retrospective study.

FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma.

Objective: The purpose of this study was to establish the predictive value of (18)F-FDG parameters for overall survival in biopsy-proven recurrent head and neck squamous cell cancer (HNSCC) patients after definitive chemoradiotherapy.

Materials And Methods: We conducted a retrospective study including 34 patients with HNSCC who had biopsy-proven recurrence between April 2004 and March 2012 and underwent FDG PET/CT at our institution at the time of recurrence. Maximum standardized uptake value (SUVmax), peak SUV (SUVpeak), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured.

Interreader agreement and variability of FDG PET volumetric parameters in human solid tumors.

Objective: The purpose of this article is to evaluate the interreader agreement and variability of two (18)F-FDG PET parameters, metabolic tumor volume and total lesion glycolysis, in human solid tumors.

Materials And Methods: One hundred eleven patients (mean [± SD] age, 61.9 ± 12.

Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years.

Unlabelled: (18)F-FDG PET/CT is used in the follow-up of patients with head and neck squamous cell cancer (HNSCC). However, its impact on clinical decision making and patient outcome is not fully established. The objective of this study was to determine the prognostic value of (18)F-FDG PET/CT for overall survival (OS) of HNSCC patients when performed in addition to clinical assessment between 4 and 24 mo after treatment.

Impact of concurrent diagnostic level CT with PET/CT on the utilization of stand-alone CT and MRI in the management of head and neck cancer patients.

Purpose Of The Report: This study aims to determine if the expansion of a PET/CT service to include simultaneous contrast-enhanced CT with PET (PET/DCT) leads to a reduction of supplemental diagnostic CT (sCT) performed within a 6-month period centered around PET/CT for initial treatment planning of patients with head and neck cancers.

Patients And Methods: There were 91 patients with head and neck cancers who had a non-contrast-enhanced PET/CT with CT (PET/aCT), and 153 patients had a PET/DCT. We compared the utilization of sCT before and after PET/aCT or PET/DCT.

FDG PET/CT in the management of primary pleural tumors and pleural metastases.

OBJECTIVE. FDG PET/CT is emerging as an important modality in the evaluation of pleural tumors. PET/CT has an established role in the diagnosis and staging and shows promise in therapy planning, therapy response assessment, and providing prognostic information in patients with malignant pleural mesothelioma.

FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma.

This article discusses the value of F-fluoro-2-deoxyglucose PET/CT imaging biomarkers in head and neck squamous cell carcinoma. F-fluoro-2-deoxyglucose PET/CT is valuable at baseline staging, radiotherapy planning, therapy response assessment and in the follow-up of patients with head and neck squamous cell carcinoma. Maximum and peak standardized uptake value (SUV and SUV), metabolic tumor volume and total lesion glycolysis are the common F-fluoro-2-deoxyglucose quantitative parameters that have been studied, along with qualitative assessments.